FDA blasts Merck's bid for adjuvant Keytruda in TNBC before adcomm, calling late-stage data 'questionable'
Merck’s Keytruda has had few obstacles in its way on the path to dominating the I-O field, which has made the New Jersey drugmaker mostly …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
